Tuesday, January 13, 2009

BiPar Sciences Raises $20M In Debt, Equity

Brisbane, California-based BiPar Sciences, a biopharmaceuticals firm focused on treatments for breast cancer, said Tuesday morning that it has raised $20M in a combination of equity and venture debt. The firm said the funding came from its existing investors, Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners. The venture debt portion came from Lighthouse Capital partners. BiPar did not break down the portion of the funding which was equity versus debt. The firm said the funding more than doubles its cash resources. BiPar is in Phase 2 traisl of a PARP inhibitor, targeted at helping to treat metastatic triple negative breast cancer. More information »